Elliot Chartash
Merck & Co., Inc., Rahway, NJ, USA (United States) · 65 works · 7,431 citations · h-index 27
Top works
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
- Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.
- Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
- Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome
- Cardiac manifestations of the antiphospholipid syndrome
- A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
- Oligoclonality of V β 3 TCR chains in the CD8+ T cell population of rheumatoid arthritis patients
- Systemic lupus erythematosus complicated by thrombotic microangiopathy
- First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
- Tendon rupture in systemic lupus erythematosus
- Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial
- Clonal expansion is a characteristic feature of the B-cell repertoire of patients with rheumatoid arthritis
- A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.
- Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis.
- Human immunodeficiency virus infection of helper T cell clones. Early proliferative defects despite intact antigen-specific recognition and interleukin 4 secretion.
- Septic subdeltoid bursitis
- Reversible monocular blindness complicating Churg-Strauss syndrome.